Lansoprazole Versus Mosapride for Functional Dyspepsia

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Functional dyspepsia is a common symptom complex with significant impact on quality of life. There is no standard treatment for functional dyspepsia but therapeutic efficacy of proton pump inhibitor (PPI) and prokinetic agent have been proved in subsets of patients. This study has two aims:

• first is to compare the therapeutic efficacy of lansoprazole (a PPI) and mosapride (a prokinetic agent) for functional dyspepsia

• second is to investigate whether different subgroups of functional dyspepsia (e.g., epigastric pain syndrome and postprandial distress syndrome) respond differently to PPI and prokinetic agent.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lotung Poh-Ai Hospital
• Collaborator: Tomorrow Medical Foundation
• Treatments: Dexlansoprazole; Lansoprazole; Mosapride

Criteria

Inclusion Criteria:

• aged more than 20 years old

• diagnosis of functional dyspepsia by fulfilling Rome-III criteria

• outpatient

Exclusion Criteria:

• aged less than 20 years

• organic lesions including ulcers, tumors, bleeding, vasculopathy or esophagitis as demonstrated on upper endoscopy

• concurrent illness with malignancy, diabetes mellitus, liver cirrhosis, renal failure or porphyria

• diagnosis of organic disease for dyspeptic symptoms by treating physicians

• history of abdominal surgery

• concurrent user of aspirin and NSAID

• history of allergy or severe side effects to lansoprazole or mosapride

• pregnant or lactating women